Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Oral compound may replace intravenous chemotherapy after surgery, data show
June 23rd, 2005
Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, strengthens evidence that Xeloda (capecitabine), an oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting. In March, 2005, Roche received approval from the European authorities for Xeloda to be used as a post-surgery treatment in colon cancer patients. The data, in the adjuvant setting, demonstrate that Xeloda provides a treatment option with benefits for colon cancer patients. The study found Xeloda to be at least as...
Source: Women's Health Weekly (2005-06-23)
|
